Loading
Life sciences · Journal article
Applied and Computational Engineering · August 18, 2026
A consensus or society position rather than new primary data.
This is a narrative review of approaches to predicting drug combination synergy using network medicine and artificial intelligence. It does not report original empirical results, but rather synthesizes the state of methods, applications, and limitations in the field, identifying data sparsity, negative-sample bias, model interpretability, and lack of prospective validation as key gaps.
Narrative review. Applications discussed in cancer, hypertension and other complex diseases; no specific clinical cohort studied..
Network medicine integrates protein-protein interaction networks, disease modules and drug-target topology to assess combination rationale. Artificial intelligence can learn nonlinear features from heterogeneous data including chemical structures, targets, omics profiles and cellular phenotypes. Approaches compared include network topology methods, conventional machine learning, graph neural networks and multimodal fusion models.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review is useful for researchers and clinicians seeking an overview of computational and systems biology approaches to rational drug combination design, but does not provide evidence from a clinical trial or empirical validation study to guide immediate clinical practice changes.
A narrative review synthesizing methods and progress in network medicine and AI-based drug combination prediction, without reporting original empirical results or clinical trials.
As stated by the source record.
This review is useful for researchers and clinicians seeking an overview of computational and systems biology approaches to rational drug combination design, but does not provide evidence from a clinical trial or empirical validation study to guide immediate clinical practice changes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Drug combination therapy can improve the treatment of complex diseases through multi-target intervention, but the number of candidate combinations expands rapidly with the size of the drug space, making purely high-throughput screening insufficient for research and clinical needs. Network medicine provides biological priors for assessing the rationale of combinations by integrating protein-protein interaction networks, disease modules and drug-target topology, whereas artificial intelligence can learn nonlinear features from heterogeneous data such as chemical structures, targets, omics profiles and cellular phenotypes. This review summarizes recent progress in drug combination synergy prediction based on network medicine and artificial intelligence. It compares network topology methods, conventional machine learning, graph neural networks and multimodal fusion models in terms of principles, applicable scenarios and limitations, and discusses their translational value in cancer, hypertension and other complex diseases. Current studies remain constrained by data sparsity, negative-sample bias, insufficient model interpretability and limited prospective validation. Future work should strengthen standardized data integration, mechanism-constrained modeling and joint dose-timing optimization to improve interpretability, generalizability and clinical usability.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.